The activity and toxicity of gemcitabine and paclitaxel in previously treated patients with small cell lung cancer (SCLC); preliminary results

F. El Ghani, K. W. Maas, N. J. Schloesser, F. M. Schramel (Nieuwegein, Utrecht, The Netherlands)

Source: Annual Congress 2004 - Chemotherapy, targeted therapies costs and outcomes
Session: Chemotherapy, targeted therapies costs and outcomes
Session type: Thematic Poster Session
Number: 1936
Disease area: Respiratory infections, Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. El Ghani, K. W. Maas, N. J. Schloesser, F. M. Schramel (Nieuwegein, Utrecht, The Netherlands). The activity and toxicity of gemcitabine and paclitaxel in previously treated patients with small cell lung cancer (SCLC); preliminary results. Eur Respir J 2004; 24: Suppl. 48, 1936

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

Treatment of advanced and metastatic non small cell lung carcinoma (NSCLC) with a new schedule of gemcitabine (GEM) plus cisplatin (CDDP)
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002

Compassionate-use gefitinib in non–small cell lung cancer (NSCLC): results from a US expanded access program (EAP)
Source: Eur Respir J 2004; 24: Suppl. 48, 231s
Year: 2004

Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study
Source: Eur Respir J 2003; 22: Suppl. 45, 28s
Year: 2003

Once a day (QD) thoracic radiotherapy (XRT) for patients with limited stage small-cell lung cancer (SCLC) treated concurrently with etoposide and cisplatin (EP): results of a single institution retrospective experience
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007


A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003

Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006

A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005


A study of paclitaxel in two dose combinations with carboplatin in the treatment of small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 319s
Year: 2001

Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003

C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004

A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 186s
Year: 2002

Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status
Source: Eur Respir J 2003; 22: Suppl. 45, 528s
Year: 2003

The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 672s
Year: 2004

Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012


Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 395s
Year: 2001

A Phase II study of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Clinical study for monochemotherapy of amrubicin, a topoisomerase II inhibitor, in patients with previously treated small cell lung cancer
Source: Eur Respir J 2007; 30: Suppl. 51, 433s
Year: 2007